TY - JOUR
T1 - Rhabdomyolysis resulting from pharmacologic interaction between erlotinib and simvastatin
AU - Veeraputhiran, Muthu
AU - Sundermeyer, Mark
PY - 2008/7
Y1 - 2008/7
N2 - Erlotinib is an epidermal growth factor receptor inhibitor indicated as a second line of therapy for locally advanced and metastatic non - small-cell lung cancer after the failure of 1 previous chemotherpy. Simvastatin belongs to the statin family used to lower blood cholesterol. Drug interaction between erlotinib and statin has not been reported before. Both drugs are major substrates of the CYP3A4 enzyme in the liver. Thus, co-administration of these drugs can increase their serum levels, potentially leading to adverse effects. We report the interaction between erlotinib and simvastatin leading to rhabdomyolysis. Thus, caution is required with increasing usage of both of these drugs.
AB - Erlotinib is an epidermal growth factor receptor inhibitor indicated as a second line of therapy for locally advanced and metastatic non - small-cell lung cancer after the failure of 1 previous chemotherpy. Simvastatin belongs to the statin family used to lower blood cholesterol. Drug interaction between erlotinib and statin has not been reported before. Both drugs are major substrates of the CYP3A4 enzyme in the liver. Thus, co-administration of these drugs can increase their serum levels, potentially leading to adverse effects. We report the interaction between erlotinib and simvastatin leading to rhabdomyolysis. Thus, caution is required with increasing usage of both of these drugs.
KW - CYP3A4
KW - Drug interaction
KW - Hepatotoxicity
KW - Pravastatin
UR - http://www.scopus.com/inward/record.url?scp=49249107124&partnerID=8YFLogxK
U2 - 10.3816/CLC.2008.n.036
DO - 10.3816/CLC.2008.n.036
M3 - Article
C2 - 18650173
AN - SCOPUS:49249107124
SN - 1525-7304
VL - 9
SP - 232
EP - 234
JO - Clinical Lung Cancer
JF - Clinical Lung Cancer
IS - 4
ER -